AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca is conducting a Phase III clinical trial titled ‘SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.’ The study aims to demonstrate the superiority of AZD9833 combined with palbociclib over anastrozole with palbociclib in treating ER-positive, HER2-negative advanced breast cancer.
The intervention being tested is AZD9833, an oral selective estrogen receptor degrader (SERD), combined with palbociclib, a CDK4/6 inhibitor. The study compares this combination to anastrozole, an aromatase inhibitor, with palbociclib, aiming to improve treatment outcomes for patients.
This randomized, double-blind study involves two groups: one receiving AZD9833 with palbociclib and a placebo for anastrozole, and the other receiving anastrozole with palbociclib and a placebo for AZD9833. The primary purpose is treatment, with triple masking to ensure unbiased results.
The study began on January 28, 2021, and is currently active but not recruiting. The last update was submitted on July 7, 2025. These dates are crucial for tracking the study’s progress and potential market impact.
The update on this study could influence AstraZeneca’s stock performance positively, as successful results may enhance its competitive edge in the oncology market. Investors should monitor this study’s outcomes, considering the competitive landscape in breast cancer treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.